Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07783269 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT07783269 · ClinicalTrials.gov record · last posted 2026-08-24

A Basket Study of CTA313 in Participants With Active Autoimmune Diseases

Study acronym: ALLNEW
StatusNot Yet Recruiting
PhasePhase 1
SponsorImviva Bio
Started2026-12
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The goal of the ALLNEW clinical trial is to learn if CTA313 UCART is safe and effective for patients with immune mediated disorders. Participants with SLE, pMS and AIE between the ages of 18 and 75 will be eligible to participate. Participants will receive one infusion of CTA313 on Day 0. During the Dose Confirmation portion, cohorts will be independently evaluated for safety and to establish the RP2D of CTA313. During the Cohort Expansion portion of the study patients will be evaluated to further confirm the efficacy and safety of CTA313. Patients will be followed for up to 24 months in this study and will be required to enroll under a separate long term follow up protocol to be followed for up to 15 years.
Trial Details
NCT Number NCT07783269
Lead Sponsor Imviva Bio
Conditions Systemic Lupus Erthematosus (SLE), Progressive Multiple Sclerosis (PMS), Autoimmune Encephalitis
Enrollment 81 participants
Start Date 2026-12
Primary Completion 2029-06 (estimated)
Study Completion 2029-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-24